Psychometric properties of the portuguese version of the chronic urticaria quality of life questionnaire (CU-Q
Chronic urticaria
Patient Reported Outcome Measures
Quality of life
Reproducibility of results
Journal
Health and quality of life outcomes
ISSN: 1477-7525
Titre abrégé: Health Qual Life Outcomes
Pays: England
ID NLM: 101153626
Informations de publication
Date de publication:
30 Dec 2019
30 Dec 2019
Historique:
received:
03
01
2019
accepted:
19
12
2019
entrez:
1
1
2020
pubmed:
1
1
2020
medline:
24
3
2020
Statut:
epublish
Résumé
Chronic urticaria is defined as the appearance of urticarial lesions and/or angioedema during a period of more than six weeks. We aimed at developing the Portuguese version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q The forward-backward approach to a linguistic equivalence was followed, after which a clinical review and a cognitive debriefing with patients were performed. The intraclass correlation coefficient checked test-retest reliability with patients filling the same questionnaire with one week apart and the Cronbach's alpha indicator assessed the internal consistency. Construct validity was tested by an exploratory factor analysis and by hypothesis tests involving sociodemographic and clinical patient characteristics, including the urticaria control test (UCT). On the other hand, criterion validity was tested through correlations with the Short-Form Health Survey SF-36, EQ-5D-5 L, and the Dermatology Quality of Life Index (DLQI). A total of 162 patients from seven hospital units were included. The mean (standard deviation) age was 42.6 (13.3) and 81.6% were female. CU-Q The satisfactory metric properties confirmed the cultural adaptation and validity of CU-Q Not applicable.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic urticaria is defined as the appearance of urticarial lesions and/or angioedema during a period of more than six weeks. We aimed at developing the Portuguese version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q
METHODS
METHODS
The forward-backward approach to a linguistic equivalence was followed, after which a clinical review and a cognitive debriefing with patients were performed. The intraclass correlation coefficient checked test-retest reliability with patients filling the same questionnaire with one week apart and the Cronbach's alpha indicator assessed the internal consistency. Construct validity was tested by an exploratory factor analysis and by hypothesis tests involving sociodemographic and clinical patient characteristics, including the urticaria control test (UCT). On the other hand, criterion validity was tested through correlations with the Short-Form Health Survey SF-36, EQ-5D-5 L, and the Dermatology Quality of Life Index (DLQI).
RESULTS
RESULTS
A total of 162 patients from seven hospital units were included. The mean (standard deviation) age was 42.6 (13.3) and 81.6% were female. CU-Q
CONCLUSIONS
CONCLUSIONS
The satisfactory metric properties confirmed the cultural adaptation and validity of CU-Q
TRIAL REGISTRATION NUMBER
BACKGROUND
Not applicable.
Identifiants
pubmed: 31888747
doi: 10.1186/s12955-019-1266-y
pii: 10.1186/s12955-019-1266-y
pmc: PMC6937665
doi:
Types de publication
Journal Article
Multicenter Study
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
190Références
Br J Dermatol. 1997 Feb;136(2):197-201
pubmed: 9068731
Allergy. 2003 Jul;58(7):621-3
pubmed: 12823121
Acta Med Port. 2000 Jan-Apr;13(1-2):55-66
pubmed: 11059056
Acta Med Port. 2016 Nov;29(11):763-781
pubmed: 28229846
Acta Med Port. 2019 Feb 28;32(2):133-140
pubmed: 30896394
J Investig Allergol Clin Immunol. 2004;14(3):214-20
pubmed: 15552715
J Allergy Clin Immunol. 2014 May;133(5):1365-72, 1372.e1-6
pubmed: 24522090
Clin Exp Dermatol. 2010 Dec;35(8):869-73
pubmed: 20456386
Qual Life Res. 2010 May;19(4):539-49
pubmed: 20169472
Acta Derm Venereol. 2012 Jul;92(4):419-25
pubmed: 21918791
Allergy. 2005 Aug;60(8):1073-8
pubmed: 15969690
Asian Pac J Allergy Immunol. 2016 Jun;34(2):137-45
pubmed: 27007835
Isr Med Assoc J. 2016 Aug;18(8):461-465
pubmed: 28471576
Health Econ. 2018 Jan;27(1):7-22
pubmed: 28833869
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
J Dermatol Sci. 2011 Apr;62(1):36-41
pubmed: 21333502
Allergy. 2011 Nov;66(11):1487-93
pubmed: 21899558
Dermatology. 2013;226(4):371-9
pubmed: 23942323
Allergy. 2003 Dec;58(12):1224-34
pubmed: 14616095
Allergy. 2009 Jun;64(6):927-36
pubmed: 19453340
J Investig Allergol Clin Immunol. 2008;18(6):426-32
pubmed: 19123433
Allergy. 2018 Jul;73(7):1393-1414
pubmed: 29336054
J Allergy Clin Immunol. 2000 Apr;105(4):664-72
pubmed: 10756214
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
J Clin Epidemiol. 2007 Jan;60(1):34-42
pubmed: 17161752
Value Health. 2008 May-Jun;11(3):509-21
pubmed: 18179659
Qual Life Res. 2019 Dec;28(12):3163-3175
pubmed: 31201730
Allergy. 2016 Jun;71(6):780-802
pubmed: 26991006
Iran J Allergy Asthma Immunol. 2014 Aug;13(4):278-85
pubmed: 24659164
World Allergy Organ J. 2018 Nov 16;11(1):32
pubmed: 30464782
J Dtsch Dermatol Ges. 2014 Nov;12(11):997-1007; quiz 1008-9
pubmed: 25273223